AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01176227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kyodophilus multi-strain probiotic capsules
Description: The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
Study NCT01176227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Kyodophilus Matching Placebo Capsules
Description: Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
Study NCT00550095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Study NCT01495585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Commercially approved products used to test the research hypothesis
Study NCT01495585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT03795675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Cochlear implant device to be implanted at time of surgical intervention.
Study NCT00719004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the foot
Description: These volunteers will have one ultrasound scan of each foot
Study NCT03730987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Intervention
Description: Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
Study NCT01377194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Study NCT01377194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Study NCT01377194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study NCT02418000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: Single Group Assignment
Study NCT02323854 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation
Description: Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
Study NCT02323854 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Resection
Description: The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
Study NCT03266120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Art
Description: Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
Study NCT03266120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gardening
Description: Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
Study NCT01999595 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control TENS
Description: Control TENS was the application of electrical stimulation via skin with no current
Study NCT01999595 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it
Study NCT01999595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency TENS with large pads
Description: High frequency TENS was delivered on large electrodes
Study NCT01999595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency TENS with large pads
Description: Low frequency TENS was delivered on large electrodes
Study NCT01999595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency TENS with small pads
Description: High frequency TENS was delivered on small electrodes
Study NCT01999595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency TENS with small pads
Description: Low frequency TENS was delivered on small electrodes
Study NCT03462238 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection for Ppi assay
Description: A 4.5 ml blood sample will be taken with a citrate vacuum tube.
Study NCT03462238 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CT Scan
Description: A scanner will be performed
Study NCT02780544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact
Description: skin-to-skin contact with parent during eye examination.
Study NCT00177892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep disruption
Description: experimentally-induced Sleep Fragmentation
Study NCT00177892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleep disruption
Description: experimentally-induced Sleep Fragmentation
Study NCT00177892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep with and without positive pressure
Description: OSAH patients with and without chronic positive airway pressure therapy
Study NCT01883427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo containing saline+glucose
Study NCT01883427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose oxidase
Description: a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
Study NCT03920631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule
Study NCT03920631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microtransplantation
Description: HLA-mismatched peripheral blood stem cells
Study NCT01083095 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sporozoite Challenge Model for Plasmodium vivax in Humans
Description: Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
Study NCT02780544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: incubator
Description: staying in incubator during eye examination.
Study NCT03999892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHIEVE
Description: The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (\~20-30 minutes) and group exercise (\~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
Study NCT01976832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music with movement
Description: Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
Study NCT01976832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social interaction
Description: The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period.
Study NCT00656630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
Study NCT00656630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50mg capsule, Once daily, 1 week duration
Study NCT00656630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsule, 1 week duration
Study NCT00682188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Intervention
Description: Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
Study NCT00682188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Intervention
Description: Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
Study NCT03858946 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simple trapeziectomy
Description: A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
Study NCT03858946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weilby
Description: The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
Study NCT03088254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)
Description: Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
Study NCT03088254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)
Description: Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
Study NCT03088254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)
Description: Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
Study NCT01965288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
Study NCT02780544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: oral sucrose before eye examination
Study NCT01965288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
Study NCT02780544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: oral sucrose before eye examination
Study NCT03318016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 MG
Description: ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
Study NCT03318016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 1000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study NCT03318016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 2000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study NCT03318016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 3000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study NCT01965288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
Study NCT01965288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
Study NCT01243359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT01243359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01243359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01243359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01243359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Undergo FLT PET/CT
Study NCT01243359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FLT PET/CT
Study NCT01243359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FLT PET/CT
Study NCT03318016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 4000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study NCT00855491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phaco
Description: AcrySof Single-Piece IOL
Study NCT00855491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco
Description: AcrySof Single-Piece IOL
Study NCT02510378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy.
Study NCT04056195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703
Description: The SKI-O-703 capsules will contain 100 mg of drug substance.
Study NCT04056195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo capsules are filled with microcrystalline cellulose.
Study NCT02816489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA
Description: (passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
Study NCT02816489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA
Description: (conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
Study NCT04056195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo capsules are filled with microcrystalline cellulose.
Study NCT00592566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, desmopressin
Description: 200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
Study NCT03791775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol foam (Atossisclerol® 3%)
Description: The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
Study NCT01995799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ferumoxytol enhanced MRI
Description: Ferumoxytol enhanced MRI scan
Study NCT00603746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X
Study NCT01318096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and tenofovir and lamivudine
Description: raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
Study NCT01318096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz+tenofovir+lamivudine
Description: efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
Study NCT00563953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal pegylated doxorubicine
Description: Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
Study NCT01104636 — intervention group
Intervention type: DRUG
Intervention: Varenicline
Description: varenicline tablets prescribed as per local German SmPC for 12 weeks duration
Study NCT03664752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: IDP-120 Gel, once-daily application
Study NCT03664752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-120 Vehicle Gel
Description: IDP-120 Vehicle Gel, once-daily application
Study NCT01524627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
Study NCT01524627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.